Literature DB >> 25480496

Minimal residual disease monitored after induction therapy by RQ-PCR can contribute to tailor treatment of patients with t(8;21) RUNX1-RUNX1T1 rearrangement.

Martina Pigazzi1, Elena Manara2, Barbara Buldini2, Valzerda Beqiri2, Valeria Bisio2, Claudia Tregnago2, Roberto Rondelli3, Riccardo Masetti3, Maria Caterina Putti2, Franca Fagioli4, Carmelo Rizzari5, Andrea Pession3, Franco Locatelli6, Giuseppe Basso2.   

Abstract

Entities:  

Keywords:  AIEOP; AML; AML1-ETO; CBFB-MYH11; RQ-PCR; RUNX1-RUNX1T1; inv(16); molecular MRD; pediatric; t(8;21)

Mesh：

Substances：

Year:  2014        PMID： 25480496      PMCID： PMC4349288          DOI： 10.3324/haematol.2014.114579

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  14 in total

1.  Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial.

Authors:  Jeffrey E Rubnitz; Hiroto Inaba; Gary Dahl; Raul C Ribeiro; W Paul Bowman; Jeffrey Taub; Stanley Pounds; Bassem I Razzouk; Norman J Lacayo; Xueyuan Cao; Soheil Meshinchi; Barbara Degar; Gladstone Airewele; Susana C Raimondi; Mihaela Onciu; Elaine Coustan-Smith; James R Downing; Wing Leung; Ching-Hon Pui; Dario Campana
Journal:  Lancet Oncol       Date:  2010-05-05       Impact factor: 41.316

2.  Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study.

Authors:  Martin Schrappe; Maria Grazia Valsecchi; Claus R Bartram; André Schrauder; Renate Panzer-Grümayer; Anja Möricke; Rosanna Parasole; Martin Zimmermann; Michael Dworzak; Barbara Buldini; Alfred Reiter; Giuseppe Basso; Thomas Klingebiel; Chiara Messina; Richard Ratei; Giovanni Cazzaniga; Rolf Koehler; Franco Locatelli; Beat W Schäfer; Maurizio Aricò; Karl Welte; Jacques J M van Dongen; Helmut Gadner; Andrea Biondi; Valentino Conter
Journal:  Blood       Date:  2011-06-30       Impact factor: 22.113

3.  Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial.

Authors:  John A Liu Yin; Michelle A O'Brien; Robert K Hills; Sarah B Daly; Keith Wheatley; Alan K Burnett
Journal:  Blood       Date:  2012-08-08       Impact factor: 22.113

4.  Response-guided induction therapy in pediatric acute myeloid leukemia with excellent remission rate.

Authors:  Jonas Abrahamsson; Erik Forestier; Jesper Heldrup; Kirsi Jahnukainen; Olafur G Jónsson; Birgitte Lausen; Josefine Palle; Bernward Zeller; Henrik Hasle
Journal:  J Clin Oncol       Date:  2010-12-13       Impact factor: 44.544

5.  Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98.

Authors:  Ursula Creutzig; Martin Zimmermann; Dirk Reinhardt; Michael Dworzak; Jan Stary; Thomas Lehrnbecher
Journal:  J Clin Oncol       Date:  2004-11-01       Impact factor: 44.544

6.  MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial.

Authors:  Hong-Hu Zhu; Xiao-Hui Zhang; Ya-Zhen Qin; Dai-Hong Liu; Hao Jiang; Huan Chen; Qian Jiang; Lan-Ping Xu; Jin Lu; Wei Han; Li Bao; Yu Wang; Yu-Hong Chen; Jing-Zhi Wang; Feng-Rong Wang; Yue-Yun Lai; Jun-Yue Chai; Li-Ru Wang; Yan-Rong Liu; Kai-Yan Liu; Bin Jiang; Xiao-Jun Huang
Journal:  Blood       Date:  2013-03-27       Impact factor: 22.113

7.  Results of the AIEOP AML 2002/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia.

Authors:  Andrea Pession; Riccardo Masetti; Carmelo Rizzari; Maria Caterina Putti; Fiorina Casale; Franca Fagioli; Matteo Luciani; Luca Lo Nigro; Giuseppe Menna; Concetta Micalizzi; Nicola Santoro; Anna Maria Testi; Marco Zecca; Andrea Biondi; Martina Pigazzi; Sergio Rutella; Roberto Rondelli; Giuseppe Basso; Franco Locatelli
Journal:  Blood       Date:  2013-05-14       Impact factor: 22.113

8.  CBFA2T3-GLIS2 fusion transcript is a novel common feature in pediatric, cytogenetically normal AML, not restricted to FAB M7 subtype.

Authors:  Riccardo Masetti; Martina Pigazzi; Marco Togni; Annalisa Astolfi; Valentina Indio; Elena Manara; Rita Casadio; Andrea Pession; Giuseppe Basso; Franco Locatelli
Journal:  Blood       Date:  2013-02-13       Impact factor: 22.113

9.  Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow.

Authors:  Giuseppe Basso; Marinella Veltroni; Maria Grazia Valsecchi; Michael N Dworzak; Richard Ratei; Daniela Silvestri; Alessandra Benetello; Barbara Buldini; Oscar Maglia; Giuseppe Masera; Valentino Conter; Maurizio Arico; Andrea Biondi; Giuseppe Gaipa
Journal:  J Clin Oncol       Date:  2009-10-05       Impact factor: 44.544

10.  Results of a randomized trial in children with Acute Myeloid Leukaemia: medical research council AML12 trial.

Authors:  Brenda E S Gibson; David K H Webb; Andrew J Howman; Siebold S N De Graaf; Christine J Harrison; Keith Wheatley
Journal:  Br J Haematol       Date:  2011-09-09       Impact factor: 6.998
View more
  12 in total

1.  Clinical significance of increased PML-RARa transcripts after induction therapy for acute promyelocytic leukaemia.

Authors:  Mi Liang; Lei Wang; Min Xiao; Jie Xiong; Jin Wang; Zhiqiong Wang; Wei Huang; Jianfeng Zhou
Journal:  Ann Med       Date:  2020-04-23       Impact factor: 4.709

2.  Characterization of children with FLT3-ITD acute myeloid leukemia: a report from the AIEOP AML-2002 study group.

Authors:  E Manara; G Basso; M Zampini; B Buldini; C Tregnago; R Rondelli; R Masetti; V Bisio; M Frison; K Polato; G Cazzaniga; G Menna; F Fagioli; P Merli; A Biondi; A Pession; F Locatelli; M Pigazzi
Journal:  Leukemia       Date:  2016-06-28       Impact factor: 11.528

3.  Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.

Authors:  Matthew P Mulé; Gabriel N Mannis; Brent L Wood; Jerald P Radich; Jimmy Hwang; Nestor R Ramos; Charalambos Andreadis; Lloyd Damon; Aaron C Logan; Thomas G Martin; Christopher S Hourigan
Journal:  Biol Blood Marrow Transplant       Date:  2016-08-17       Impact factor: 5.742

4.  Gene mutational pattern and expression level in 560 acute myeloid leukemia patients and their clinical relevance.

Authors:  Yong-Mei Zhu; Pan-Pan Wang; Jin-Yan Huang; Yun-Shuo Chen; Bing Chen; Yu-Jun Dai; Han Yan; Yi Hu; Wen-Yan Cheng; Ting-Ting Ma; Sai-Juan Chen; Yang Shen
Journal:  J Transl Med       Date:  2017-08-22       Impact factor: 5.531

5.  [Prognostic value of dynamic monitoring of RUNX1-RUNX1T1 transcript in pediatric acute myeloid leukemia].

Authors:  H T Gao; Y Zhang; K Sun; J M Guo; Y Q Chen; X L Chen; J Shi; X N Niu; F Wang; L Huo
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2017-03-14

6.  In-silico comparison of two induction regimens (7 + 3 vs 7 + 3 plus additional bone marrow evaluation) in acute myeloid leukemia treatment.

Authors:  Jan Christoph Banck; Dennis Görlich
Journal:  BMC Syst Biol       Date:  2019-01-31

Review 7.  Flow-Cytometric Monitoring of Minimal Residual Disease in Pediatric Patients With Acute Myeloid Leukemia: Recent Advances and Future Strategies.

Authors:  Barbara Buldini; Margarita Maurer-Granofszky; Elena Varotto; Michael N Dworzak
Journal:  Front Pediatr       Date:  2019-10-11       Impact factor: 3.418

8.  Molecular characterization of AML with RUNX1-RUNX1T1 at diagnosis and relapse reveals net loss of co-mutations.

Authors:  Alexander Höllein; Niroshan Nadarajah; Manja Meggendorfer; Sabine Jeromin; Wolfgang Kern; Claudia Haferlach; Torsten Haferlach
Journal:  Hemasphere       Date:  2019-02-04

Review 9.  Sequencing-Based Measurable Residual Disease Testing in Acute Myeloid Leukemia.

Authors:  Jennifer M Yoest; Cara Lunn Shirai; Eric J Duncavage
Journal:  Front Cell Dev Biol       Date:  2020-05-08

10.  Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation.

Authors:  Ya-Zhen Qin; Yu Wang; Hong-Hu Zhu; Robert Peter Gale; Mei-Jie Zhang; Qian Jiang; Hao Jiang; Lan-Ping Xu; Huan Chen; Xiao-Hui Zhang; Yan-Rong Liu; Yue-Yun Lai; Bin Jiang; Kai-Yan Liu; Xiao-Jun Huang
Journal:  Chin J Cancer       Date:  2016-05-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.